Efficacy Offsets High Costs for Immunotherapy in US, But Not Overseas – Curetoday.com
|
Efficacy Offsets High Costs for Immunotherapy in US, But Not Overseas
Curetoday.com Researchers from Israel, the United Kingdom (UK) and Canada sought to determine the cost-effectiveness of Keytruda for the second-line treatment of patients with advanced bladder cancer. Drug costs were compared between the US, UK, Canada and Australia … |
